← XTL BIOPHARMACEUTICALS LTD
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — | — | $41k |
$451k
+1000.00%
|
— | $0 | |
| Revenue From Interest | — | — | — | — | — | — | — | $41k | $34k | — | — | |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | $31k |
$338k
+1000.00%
|
— | $0 | |
| Gross Profit (derived) | — | — | — | — | — | — | — | $10k |
$3k
-70.73%
|
— | $0 | |
| Research and development | $443k | $43k | $38k | $35k | $38k | $30k | $30k | $31k | $98k | $28k | $28k | |
| General and administrative expenses | — | ($1.2m) | ($755k) | ($807k) | ($910k) | — | ($850k) | ($734k) | ($1.6m) | ($1.4m) | $1.1m | |
| General and administrative | $1.3m | $1.2m | $755k | $807k | $910k | $1.0m | $850k | $734k | $1.6m | — | $1.1m | |
| Operating expenses: | ||||||||||||
| Operating loss | ($2.6m) |
($1.2m)
+51.35%
|
($793k)
+36.36%
|
($842k)
-6.18%
|
($948k)
-12.59%
|
($1.0m) |
($880k)
+14.65%
|
($765k)
+13.07%
|
($2.2m)
-183.92%
|
($1.7m) |
($1.4m)
+18.25%
|
|
| Interest Expense | — | — | — | — | — | — | — | — | $28k | — | $7k | |
| Loss before income taxes | — | — | — | — | — | — | ($1.3m) | ($1.8m) | ($1.2m) | ($759k) | — | |
| Deferred Tax Expense (Income) | — | — | — | — | — | — | — | — | ($130k) | — | — | |
| Income Tax Expense Continuing Operations | — | — | — | — | — | — | — | — | ($130k) | — | $0 | |
| Net loss for the year | ($2.5m) | ($781k) | $3.0m | ($1.3m) | ($782k) | $435k | ($1.3m) | ($1.8m) | ($1.0m) | ($7.0m) | — | |
| Basic Earnings (Loss) Per Share | — | — | — | — | — | $0.00 | ($0.00) | ($0.00) | ($0.00) | — | ($3.20) | |
| Diluted Earnings (Loss) Per Share | — | ($0.00) | $0.01 | ($0.00) | ($0.00) | $0.00 | ($0.00) | ($0.00) | ($0.00) | ($0.01) | ($3.20) | |
| Profit (loss) from continuing operations (in Dollars per share) | — | — | — | — | — | — | — | ($0.00) | $0.00 | ($0.00) | — | |
| Loss from discontinued operations (in Dollars per share) | — | — | — | — | — | — | — | — | ($0.00) | ($0.01) | — | |
| Weighted average number of issued ordinary shares (in Shares) | — | $470.2m | $514.2m | $514.2m | $514.2m | — | $544.9m | $544.9m | $673.0m | $896.2m | — | |
| Diluted weighted average number of ordinary shares (in Shares) | — | — | — | — | — | — | $544.9m | $544.9m | $704.2m | $896.2m | — | |
| Additional Financial Items | ||||||||||||
| Applicable Tax Rate | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | |
| Average Effective Tax Rate | — | — | — | — | — | — | $0 | — | — | — | — | |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | $3k | $9k | — | — | — | — | — | — | — | — | $31k | |
| Depreciation And Amortisation Expense | $3k | $1k | — | — | — | — | — | — | — | — | $31k | |
| Employee Benefits Expense | $551k | $424k | $312k | $302k | $329k | $276k | $276k | $243k | $605k | — | — | |
| Expense From Share-Based Payment Transactions With Employees | $175k | $37k | $22k | $5k | $51k | $37k | $14k | — | — | — | — | |
| Finance Costs | $7k | $337k | $35k | $603k | $17k | $21k | $1.6m | — | — | — | — | |
| Finance Income | $23k | $802k | $3.8m | $98k | $183k | $1.5m | $1.1m | $41k | $1.1m | — | — | |
| Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill | ($848k) | — | — | — | — | — | — | — | — | — | — | |
| Other Finance Cost | $7k | $8k | $35k | $29k | $17k | $21k | $27k | $36k | $112k | — | — | |
| Postemployment Benefit Expense Defined Contribution Plans | $17k | $11k | $6k | $6k | $2k | $0 | — | — | — | — | — | |
| Professional Fees Expense | $213k | $440k | $255k | $262k | $266k | $381k | $291k | — | — | — | — | |
| Profit Loss Attributable To Noncontrolling Interests | ($2.5m) | ($781k) | $3.0m | ($1.3m) | ($782k) | $435k | ($1.3m) | ($1.8m) | ($1.0m) | ($7.0m) | — | |
| Profit Loss Before Tax | — | — | — | — | — | — | — | ($1.8m) | ($1.2m) | — | — | |
| Profit Loss From Operating Activities | ($2.6m) | ($1.2m) | ($793k) | ($842k) | ($948k) | ($1.0m) | ($880k) | ($765k) | ($2.2m) | ($1.7m) | — | |
| Change in fair value of financial instruments | — | — | — | — | — | — | $1.1m | — | $926k | $1.1m | — | |
| Change in fair value of marketable securities | — | — | — | — | — | — | ($1.5m) | ($1.0m) | $167k | $5k | — | |
| Other finance income | — | $37k | $87k | $98k | $45k | — | $36k | $41k | $34k | $60k | — | |
| Other finance expenses | — | ($8k) | ($35k) | ($29k) | ($17k) | — | ($27k) | ($36k) | ($112k) | ($177k) | — | |
| Finance income (expenses), net | — | $465k | $3.8m | ($505k) | $166k | — | ($468k) | ($1.0m) | $1.0m | $929k | — | |
| Profit (loss) from continuing operations | — | — | — | — | — | — | — | ($1.8m) | $240k | ($759k) | — | |
| Loss from discontinued operations, net of tax | — | — | — | — | — | — | — | — | ($1.3m) | ($6.2m) | — |